In today's fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies before making investment decisions. In this article, we will conduct a comprehensive industry comparison, evaluating Eli Lilly (NYSE:LLY) against its key competitors in the Pharmaceuticals industry. By examining key financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
Eli Lilly Background
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
---|---|---|---|---|---|---|---|
Eli Lilly and Co | 120.95 | 56.49 | 18.81 | -0.52% | $0.96 | $7.64 | 36.84% |
Novo Nordisk A/S | 42.14 | 32.81 | 15.19 | 22.01% | $28.51 | $55.85 | 36.95% |
Merck & Co Inc | 902.93 | 7.77 | 5.48 | 11.87% | $6.95 | $11.7 | 6.71% |
Novartis AG | 25.30 | 4.54 | 4.65 | 19.99% | $4.18 | $8.75 | 7.39% |
AstraZeneca PLC | 34.73 | 5.47 | 4.55 | 3.68% | $3.33 | $9.4 | 4.64% |
Zoetis Inc | 38.50 | 17.09 | 10.48 | 12.28% | $0.9 | $1.51 | 7.44% |
GSK PLC | 13.39 | 4.95 | 2.18 | 2.64% | $1.78 | $5.63 | -1.17% |
Takeda Pharmaceutical Co Ltd | 37.33 | 0.98 | 1.59 | -0.69% | $202.28 | $699.51 | 4.07% |
Viatris Inc | 7.85 | 0.68 | 0.93 | 1.59% | $1.22 | $1.69 | -3.34% |
Dr Reddy's Laboratories Ltd | 19.14 | 3.73 | 3.68 | 5.29% | $22.42 | $42.2 | 6.57% |
Jazz Pharmaceuticals PLC | 148.06 | 2.22 | 2.26 | 4.19% | $0.33 | $0.87 | 3.35% |
Amphastar Pharmaceuticals Inc | 20.62 | 4.25 | 4.62 | 8.31% | $0.09 | $0.11 | 50.3% |
Average | 117.27 | 7.68 | 5.06 | 8.29% | $24.73 | $76.11 | 11.17% |